8-K: Kalaris Therapeutics Reports Positive TH103 Data in nAMD Trial

Kalaris Therapeutics announced positive additional data from its Phase 1a SAD clinical trial of TH103 for neovascular age-related macular degeneration (nAMD), showing improvements in vision and retinal anatomy.

Summary

• Kalaris Therapeutics has released positive additional data from the Phase 1a single ascending dose (SAD) clinical trial of its investigational drug TH103 for neovascular age-related macular degeneration (nAMD).
• The expanded dataset includes 17 treatment-naive patients and 3 treatment-experienced patients, all of whom completed six months of follow-up.
• The data show robust structural and functional improvements, with TH103 plasma pharmacokinetic findings suggesting greater intraocular retention compared to current anti-VEGF agents.
• Specifically, 41% of treatment-naive patients received a first retreatment at four months or later after a single TH103 injection, and 29% received no additional treatment during the six-month follow-up.
• Treatment-experienced patients saw their prior treatment interval extended by an average of two months after a single TH103 injection.
• At one month, treatment-naive patients showed a mean 9.2-letter BCVA improvement and an 118m improvement in mean central subfield thickness.
• No cases of intraocular inflammation (IOI) were observed in six patients treated at the 2.5 mg dose with product manufactured after process adjustments.
• The company is currently enrolling patients in its Phase 1b/2 study, with initial data expected in the first half of 2027.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, with strong clinical data supporting the therapeutic potential of TH103 and a clear path forward for further development.

Positives

• Positive additional data from the Phase 1a SAD clinical trial of TH103 in neovascular AMD patients.
• Demonstrated improvements in vision (BCVA) and retinal anatomy (OCT parameters).
• Pharmacokinetic findings suggest greater intraocular retention compared to leading anti-VEGF agents (27to 53-fold lower Cmax on a molar equivalence basis).
• Evidence of prolonged biological activity with 41% of treatment-naive patients receiving first retreatment at 4 months or later after a single injection.
• Treatment-experienced patients had their retreatment interval extended by an average of 2 months.
• Mean 9.2-letter BCVA improvement and 118m improvement in mean central subfield thickness observed at one month in treatment-naive patients.
• No cases of intraocular inflammation (IOI) observed in six patients treated at the 2.5 mg dose with adjusted manufacturing process.
• The company is on track to share initial data from the ongoing Phase 1b/2 study in the first half of 2027.

Negatives

• One patient treated at the 5 mg dose experienced transient intraocular inflammation (IOI) that resolved without sequelae.
• Two cases of mild/moderate IOI were observed at the 2.5mg dose level with an earlier manufacturing batch (#1).

Risks

• Risks associated with the clinical development and regulatory approval of TH103, including potential delays in trial completion.
• Uncertainty regarding whether early clinical trial data will be predictive of final results.
• Dependence on third parties for the development and manufacture of TH103.
• Risks related to the inability to obtain sufficient additional capital to advance the product candidate.
• Uncertainties in obtaining successful clinical results and unexpected costs.
• Ability to obtain, maintain, and protect intellectual property rights.
• Changes in regulatory requirements and government incentives.
• Competitive landscape and developments relating to competing therapies.

Future Outlook

The company is actively enrolling patients in its Phase 1b/2 study, which is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of repeated TH103 intravitreal injections. Study results will inform dose selection for potential future Phase 3 trials. Initial data from the Phase 1b/2 study are expected in the first half of 2027. The company anticipates that its cash resources will fund operations into Q4 2027.

Management Comments

• "The expanded Phase 1a SAD dataset continues to strengthen our confidence in potential TH103 differentiation," said Andrew Oxtoby, CEO of Kalaris Therapeutics.
• "The consistency of the structural, functional and pharmacokinetic findings reinforces our belief that TH103 has the potential to offer a best-in-class treatment option for patients with neovascular AMD."

Industry Context

StockSavvy.ai notes that Kalaris Therapeutics' announcement positions TH103 as a potential next-generation anti-VEGF therapy in the highly competitive and large market for neovascular age-related macular degeneration treatments. The focus on extended intraocular retention and potentially reduced dosing frequency aligns with industry trends aiming to improve patient compliance and outcomes.

Comparison to Industry Standards

• The mean 9.2-letter BCVA improvement at Month 1 for TH103 compares favorably to reported Month 1 BCVA improvements for leading agents like Eylea (ranging from approximately 53% letter gain to ~60 letters baseline mean), Vabysmo, and Eylea HD in their respective Phase 3 trials, though direct comparison is limited due to differing protocols.
• The mean 118m improvement in central subfield thickness (CST) and 93% reduction in intraretinal fluid (IRF) at Month 1 for TH103 also appears robust when compared to baseline CSTs and reported changes for current market-leading agents, though cross-trial comparisons are not directly reliable.
• TH103's pharmacokinetic profile, with 27to 53-fold lower Cmax compared to current leading anti-VEGF agents on a molar equivalence basis, suggests potentially greater intraocular retention, a key differentiator sought in the industry for longer-acting treatments.
• The time to retreatment data (41% at 4 months or later, 29% no retreatment in 6 months) suggests a potential for longer durability than typical retreatment intervals for existing therapies, which often require injections every 1-2 months.

Stakeholder Impact

• Shareholders: Positive data may increase confidence in the company's lead asset and future prospects, potentially impacting stock valuation.
• Patients with nAMD: Potential for a new treatment option with improved durability and possibly reduced dosing frequency, leading to better vision outcomes and quality of life.
• Healthcare Providers: Data supporting TH103's efficacy and durability could influence treatment decisions and practice patterns.
• Competitors: The positive results for TH103 may intensify competition in the anti-VEGF therapy market for retinal diseases.

Next Steps

• Continue enrolling and dosing patients in the ongoing Phase 1b/2 study.
• Share initial data from the Phase 1b/2 study in the first half of 2027.
• Inform dose selection for potential future Phase 3 trials based on Phase 1b/2 results.
• Pending Phase 1b/2 results, initiate potential Phase 3 trial in nAMD by year-end 2027.
• Plan expansions beyond nAMD into other VEGF-mediated diseases like DME, DR, and RVO, subject to IND clearance.

Key Dates

Recommendation

The positive clinical data for TH103 are encouraging, suggesting strong potential for the drug. However, the results are from an early-stage trial (Phase 1a), and further validation in larger Phase 1b/2 and Phase 3 trials is required. The company also faces risks related to clinical development, regulatory approval, and capital needs. Therefore, a 'hold' recommendation is appropriate pending further data and de-risking events.

Keywords

Kalaris Therapeutics, TH103, neovascular age-related macular degeneration, nAMD, Phase 1a trial, clinical data, anti-VEGF, retinal diseases